Welcome to our dedicated page for Johnson & Johnson news (Ticker: JNJ), a resource for investors and traders seeking the latest updates and insights on Johnson & Johnson stock.
Johnson & Johnson (NYSE: JNJ) generates a steady flow of news across Innovative Medicine and MedTech, reflecting its role in pharmaceutical preparation manufacturing and medical technologies. On this news page, readers can follow company announcements on clinical trial results, regulatory milestones, strategic transactions, manufacturing investments and corporate actions.
Recent oncology news includes positive topline data from the Phase 3 MajesTEC-9 study of TECVAYLI (teclistamab-cqyv) monotherapy in relapsed or refractory multiple myeloma, where Johnson & Johnson reported a substantial reduction in the risk of disease progression or death versus standard of care in a population predominantly refractory to anti-CD38 therapy and lenalidomide. The company has also shared longer-term results from the OrigAMI-1 study of RYBREVANT (amivantamab-vmjw) plus chemotherapy in metastatic colorectal cancer, supporting further Phase 3 evaluation of amivantamab-based regimens in first- and second-line settings.
In neuroscience and mental health, Johnson & Johnson has highlighted new data on CAPLYTA (lumateperone), SPRAVATO (esketamine) and the investigational agent seltorexant at major scientific meetings, including analyses focused on remission in major depressive disorder, treatment-resistant depression and sleep-related symptoms. The company has also announced positive Phase 2b results for nipocalimab in systemic lupus erythematosus and plans to initiate a Phase 3 program, underscoring its activity in autoantibody-driven diseases.
MedTech news covers developments such as the FDA submission of the OTTAVA robotic surgical system for De Novo classification, supported by an IDE study in gastric bypass procedures, and an expanded indication for the TRUFILL n‑BCA Liquid Embolic System for chronic subdural hematoma. Corporate and financial updates, including quarterly dividend declarations, U.S. manufacturing investments and government agreements to improve access to medicines, also appear in Johnson & Johnson’s news flow. Investors, clinicians and observers can use this page to monitor how Johnson & Johnson’s clinical, regulatory and strategic decisions evolve over time.
Johnson & Johnson (NYSE: JNJ) reported Week 28 Phase 2b ANTHEM-UC results for icotrokinra in moderately to severely active ulcerative colitis on Oct 27, 2025.
Key outcomes at Week 28 for the 400 mg once-daily dose: clinical remission 31.7% vs placebo 9.5%, endoscopic improvement 38.1% vs placebo 11.1%, and clinical response 66.7% vs placebo 25.4%. All tested doses (100 mg, 200 mg, 400 mg) favored icotrokinra over placebo for response, remission, endoscopic and histologic-endoscopic mucosal improvement.
Adverse event and serious adverse event rates were reported as similar across icotrokinra and placebo through Week 28. Phase 3 programs (ICONIC-UC and ICONIC-CD) are underway; an NDA for plaque psoriasis was submitted in July 2025.
Johnson & Johnson (NYSE: JNJ) reported Phase 2 DAHLIAS results published in The Lancet showing nipocalimab significantly reduced Sjögren's disease activity at Week 24 versus placebo.
Key findings: ClinESSDAI LS mean difference –2.65 (90% CI –4.03 to –1.28; p=0.0018) for nipocalimab 15 mg/kg Q2W, biomarker declines including rheumatoid factor and circulating immune complexes, and objective salivary flow improvement in 33% vs. 16% of patients (15 mg/kg vs placebo). Safety was described as tolerable with no new signals, no increase in serious infections, and no participants requiring IVIG or rescue therapy. Nipocalimab holds Breakthrough Therapy Designation (Nov 2024) and Fast Track (Apr 2025); the Phase 3 DAFFODIL study is enrolling.
Johnson & Johnson (NYSE: JNJ) reported 52-week Phase 3 ICONIC-TOTAL results for icotrokinra, an investigational oral peptide targeting the IL-23 receptor, in adolescents and adults with plaque psoriasis at high-impact sites.
Key findings: 72% scalp ss-IGA 0/1, 85% genital sPGA-G 0/1, site-specific clearance durable to Week 52; overall IGA 0/1 was 67% at Week 24 and maintained at Week 52, with 44% achieving IGA 0. Hand/foot hf-PGA 0/1 rose from 42% at Week 16 to 62% at Week 52 in a smaller subset. Adverse event and serious adverse event rates through Week 52 were similar to Week 16 with no new safety signals identified.
Johnson & Johnson (NYSE: JNJ) will present at the 7th Annual Wolfe Research Healthcare Conference on Monday, November 17, 2025. Management will take part in a Fireside Chat at 10:40 a.m. Eastern Time. A live audio webcast will be available on the company’s Investor Relations website and an archived edition will be posted later that day.
The audio webcast replay is expected to be available approximately 48 hours after the webcast. Media and investor contact emails are provided for follow-up.
Johnson & Johnson (NYSE:JNJ) reported Phase 1b/2 OrigAMI-4 results for subcutaneous amivantamab in HPV-unrelated recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) on Oct 19, 2025.
Key data: ORR 45% (38 efficacy-evaluable patients; 95% CI 29-62), median duration of response 7.2 months (95% CI 5.3-NE), tumor shrinkage in 82% of patients, and median PFS 6.8 months (95% CI 4.2-9.0). Safety across 86 patients showed common AEs: fatigue 31%, hypoalbuminemia 31%, stomatitis 23%; administration reactions 7%, discontinuation 2%.
Company is initiating Phase 3 OrigAMI-5 first-line study.
Johnson & Johnson (NYSE:JNJ) announced positive topline results from the Phase 3 MajesTEC-3 study of TECVAYLI (teclistamab-cqyv) plus DARZALEX FASPRO versus investigator's choice (DPd or DVd) in relapsed/refractory multiple myeloma with one to three prior lines of therapy.
At almost three years follow-up the combination met the primary endpoint of progression-free survival (PFS) and the secondary endpoint of overall survival (OS) with statistically significant superiority; the IDMC recommended unblinding. Safety was consistent with known monotherapy profiles. Phase 2 MajesTEC-5 earlier showed a 100% overall response rate in transplant-eligible newly diagnosed patients.
Johnson & Johnson (NYSE: JNJ) announced a cash dividend of $1.30 per share for the fourth quarter of 2025. The dividend is payable on December 9, 2025 to shareholders of record at the close of business on November 25, 2025. The ex-dividend date is November 25, 2025.
Johnson & Johnson (NYSE: JNJ) announced its intent to separate its Orthopaedics business into a standalone company to operate as DePuy Synthes. The company said the move aims to sharpen JNJ's focus on higher‑growth Innovative Medicine and MedTech areas and accelerate MedTech portfolio shifts toward higher‑margin markets. The Orthopaedics business reported ~$9.2 billion in sales for fiscal 2024 and serves a $50 billion+ global market. The company targets completion within 18–24 months and appointed Namal Nawana as Worldwide President of DePuy Synthes.
Johnson & Johnson (NYSE: JNJ) reported Q3 2025 sales of $23.99B, up 6.8% year-over-year, with operational growth of 5.4% and adjusted operational growth of 4.4%. GAAP diluted EPS was $2.12 and adjusted diluted EPS was $2.80 (+15.7% YoY). The company raised its full-year estimated reported sales guidance to a $93.7B midpoint and reaffirmed full-year adjusted EPS at a $10.85 midpoint while absorbing higher tax costs. Q3 product and pipeline highlights include U.S. approval of INLEXZO, subcutaneous TREMFYA approval in ulcerative colitis, a submission for icotrokinra, landmark overall survival data for RYBREVANT + LAZCLUZE, and long-term survival benefit for the Impella heart pump from DanGer Shock.
Johnson & Johnson (NYSE: JNJ) announced receipt of an unsolicited mini‑tender from Tutanota LLC to buy up to 500,000 shares at $145.00 per share. The offer equals about 0.0207% of JNJ outstanding shares as of the September 29, 2025 offer date and is conditioned on the closing price exceeding $145.00 on the last trading day before expiration.
Johnson & Johnson is not associated with the bidder, says the offer price is below recent market levels, warns the offer may be extended in successive 45–180 day periods, and recommends shareholders take no action and consult brokers or advisors. The offer is scheduled to expire at 5:00 p.m. ET on October 29, 2025 unless extended or terminated.